PURPOSE: To discover diagnostic biomarkers associated with early-stage non-small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in stage I patients compared with patients with advanced-stage disease. Here we describe an autoantibody against complement factor H (CFH) and this autoantibody's association with early-stage NSCLC. EXPERIMENTAL DESIGN: Immunoblots were used to detect autoantibodies in the sera of stage I NSCLC patients. An autoantibody recognizing a 150 kDa protein was discovered, and the protein was identified by mass spectrometry. The association of the autoantibody with early-stage disease was suggested by the results of immunoblot analysis with sera from 28 stage I patients and 28 stage III/IV patients. This association was confirmed by protein microarray of sera from 125 NSCLC patients of all stages as well as 125 controls matched by age, gender, and smoking history. RESULTS: The immunoreactive protein was identified as CFH. By immunoblot analysis, anti-CFH autoantibody was found in 50% of stage I NSCLC patients and 11% of late-stage NSCLC patients (P = 0.003). By protein microarray analysis, patients with stage I NSCLC had a significantly higher incidence of anti-CFH antibody than those with late-stage NSCLC (P = 0.0051). The percentage of sera with a positive level of CFH autoantibody was 30.4% in stage I, 21.1% in stage II, 12.5% in stage III, 7.4% in stage IV, and 8.0% in the control group. CONCLUSIONS: These findings suggest that in patients with NSCLC, CFH autoantibody is a molecular marker associated with early-stage disease. (c) 2010 AACR.
PURPOSE: To discover diagnostic biomarkers associated with early-stage non-small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in stage I patients compared with patients with advanced-stage disease. Here we describe an autoantibody against complement factor H (CFH) and this autoantibody's association with early-stage NSCLC. EXPERIMENTAL DESIGN: Immunoblots were used to detect autoantibodies in the sera of stage I NSCLCpatients. An autoantibody recognizing a 150 kDa protein was discovered, and the protein was identified by mass spectrometry. The association of the autoantibody with early-stage disease was suggested by the results of immunoblot analysis with sera from 28 stage I patients and 28 stage III/IV patients. This association was confirmed by protein microarray of sera from 125 NSCLCpatients of all stages as well as 125 controls matched by age, gender, and smoking history. RESULTS: The immunoreactive protein was identified as CFH. By immunoblot analysis, anti-CFH autoantibody was found in 50% of stage I NSCLCpatients and 11% of late-stage NSCLCpatients (P = 0.003). By protein microarray analysis, patients with stage I NSCLC had a significantly higher incidence of anti-CFH antibody than those with late-stage NSCLC (P = 0.0051). The percentage of sera with a positive level of CFH autoantibody was 30.4% in stage I, 21.1% in stage II, 12.5% in stage III, 7.4% in stage IV, and 8.0% in the control group. CONCLUSIONS: These findings suggest that in patients with NSCLC, CFH autoantibody is a molecular marker associated with early-stage disease. (c) 2010 AACR.
Authors: S von Mensdorff-Pouilly; A A Verstraeten; P Kenemans; F G Snijdewint; A Kok; G J Van Kamp; M A Paul; P J Van Diest; S Meijer; J Hilgers Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Ji Qiu; Gina Choi; Lin Li; Hong Wang; Sharon J Pitteri; Sandra R Pereira-Faca; Alexei L Krasnoselsky; Timothy W Randolph; Gilbert S Omenn; Cim Edelstein; Matt J Barnett; Mark D Thornquist; Gary E Goodman; Dean E Brenner; Ziding Feng; Samir M Hanash Journal: J Clin Oncol Date: 2008-09-15 Impact factor: 44.544
Authors: A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj Journal: Clin Exp Immunol Date: 2014-10 Impact factor: 4.330
Authors: George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov Journal: Nat Rev Immunol Date: 2020-01-27 Impact factor: 53.106
Authors: Ryan T Bushey; M Anthony Moody; Nathan L Nicely; Barton F Haynes; S Munir Alam; Stephen T Keir; Rex C Bentley; Kingshuk Roy Choudhury; Elizabeth B Gottlin; Michael J Campa; Hua-Xin Liao; Edward F Patz Journal: Cell Rep Date: 2016-05-05 Impact factor: 9.423
Authors: Martin Kolev; Madhumita Das; Monica Gerber; Scott Baver; Pascal Deschatelets; Maciej M Markiewski Journal: Front Immunol Date: 2022-07-01 Impact factor: 8.786
Authors: Barbara Uzonyi; Zsóka Szabó; Eszter Trojnár; Satu Hyvärinen; Katalin Uray; Helle H Nielsen; Anna Erdei; T Sakari Jokiranta; Zoltán Prohászka; Zsolt Illes; Mihály Józsi Journal: Front Immunol Date: 2021-04-27 Impact factor: 7.561
Authors: Mariana Guergova-Kuras; István Kurucz; William Hempel; Nadège Tardieu; János Kádas; Carole Malderez-Bloes; Anne Jullien; Yann Kieffer; Marina Hincapie; András Guttman; Eszter Csánky; Balázs Dezso; Barry L Karger; László Takács Journal: Mol Cell Proteomics Date: 2011-09-26 Impact factor: 5.911
Authors: Marlies E Heuvers; Joachim G Aerts; Robin Cornelissen; Harry Groen; Henk C Hoogsteden; Joost P Hegmans Journal: BMC Cancer Date: 2012-12-05 Impact factor: 4.430